Arrowhead Pharmaceuticals announced that its drug Redemplo® (Plozasiran) has received marketing authorization from the European Commission for lowering triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS).

FCS is a rare and severe genetic disease characterized by extremely high levels of triglycerides in the blood, which can lead to life-threatening pancreatitis. This approval marks a significant advancement for Arrowhead Pharmaceuticals in the field of rare disease treatments, providing a new treatment option for FCS patients in Europe. The company stated that it is committed to bringing this innovative therapy to patients in need as soon as possible.